v3.25.3

Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue
Research and development collaborations (note 9)	$ 27,614	$ 16,000	$ 103,450	$ 45,273
Operating expenses:
Research and development	35,578	36,353	105,765	97,558
General and administrative	14,146	13,852	46,082	45,321
Impairment on acquired IPR&D (note 6)	0	0	0	17,287
Total operating expenses	49,724	50,205	151,847	160,166
Loss from operations	(22,110)	(34,205)	(48,397)	(114,893)
Other income:
Interest income	3,529	4,785	10,379	15,859
Other income (expense), net (note 10)	315	(204)	(257)	214
Total other income, net	3,844	4,581	10,122	16,073
Loss before income taxes	(18,266)	(29,624)	(38,275)	(98,820)
Income tax expense	(1,336)	(226)	(1,646)	(369)
Net loss	(19,602)	(29,850)	(39,921)	(99,189)
Other comprehensive income:
Unrealized income on available for sale securities, net of tax of nil (note 5)	290	1,905	902	604
Total other comprehensive income	290	1,905	902	604
Comprehensive loss	$ (19,312)	$ (27,945)	$ (39,019)	$ (98,585)
Net loss per common share (note 4):
Basic (in dollars per share)	$ (0.26)	$ (0.39)	$ (0.53)	$ (1.30)
Diluted (in dollars per share)	$ (0.26)	$ (0.39)	$ (0.53)	$ (1.30)
Weighted-average common stock outstanding (note 4):
Basic (in shares)	75,767,778	76,128,531	75,427,508	76,244,893
Diluted (in shares)	75,775,214	76,157,101	75,434,487	76,266,177

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

Zymeworks Inc. 10-Q